abs313.txt	background		some		but	not	all		epidemiologic	evidence	supports	a	role	forcholesterol		the	precursor	for	steroid	hormone	synthesis		in	prostate	cancer	using	a	pten-null	transgenic	mouse	model	of	prostate	cancer		we	tested	the	effectof	modifying	serum	cholesterol	levels	on	prostate	tumor	development	and	growth	we	hypothesized	that	serum	cholesterol	reduction	would	lower	tumor	androgens	andslow	prostate	cancer	growth	methods		ptenloxp/loxp-cre+	mice	consuming	ad	libitum	high	fat		high	cholesteroldiets	(40%	fat		1	25%	cholesterol)	were	randomized	after	weaning	to	receive	thecholesterol	uptake	inhibitor		ezetimibe	(30	mg/kg/day)		or	no	intervention		andsacrificed	at	2		3		or	4	months	of	age		serum	cholesterol	and	testosterone	weremeasured	by	elisa	and	intraprostatic	androgens	by	mass	spectrometry		prostatehistology	was	graded		and	proliferation	and	apoptosis	in	tumor	epithelium	andstroma	was	assessed	by	ki67	and	tunel		respectively	results		ezetimibe-treated	mice	had	lower	serum	cholesterol	at	4	months(p	=	0	031)		serum	cholesterol	was	positively	correlated	with	prostate	weight(p	=	0	033)	and	tumor	epithelial	proliferation	(p	=	0	069)		and	negativelycorrelated	with	tumor	epithelial	apoptosis	(p	=	0	004)		serum	cholesterol	wasunrelated	to	body	weight	(p	=	0	195)		tumor	stromal	cell	proliferation	wasreduced	in	the	ezetimibe	group	(p	=	0	010)		increased	serum	cholesterol	at	4months	was	associated	with	elevated	intraprostatic	dhea		testosterone		andandrostenedione	(p	=	0	043		p	=	0	074		p	=	0	031		respectively)		however	cholesterol	reduction	did	not	significantly	affect	adenocarcinoma	development	at2		3		or	4	months	of	age	(0		78		and	100%	in	ezetimibe-treated	vs		0		80		and100%	in	mice	not	receiving	ezetimibe)	conclusions		though	serum	cholesterol	reduction	did	not	significantly	affect	therate	of	adenocarcinoma	development	in	the	pten-null	transgenic	mouse	model	ofprostate	cancer		it	lowered	intraprostatic	androgens	and	slowed	tumor	growth	these	findings	support	a	role	for	serum	cholesterol	in	promoting	prostate	cancergrowth		potentially	via	enhanced	tumor	androgen	signaling		and	may	provide	newinsight	into	cholesterol-lowering	interventions	for	prostate	cancer	treatment	
